:: Library Catalog

Imagen de Portada

Guardado en:

Detalles Bibliográficos
Autor principal:	Iskandar Idris
Formato:	Artículo Open Access
Publicado:	Wiley 2024
Materias:	Diabetes, Obesity and Metabolism Now
Acceso en línea:	https://dom-pubs.pericles-prod.literatumonline.com/doi/10.1002/doi2.91
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Increasing excess to weight loss injection shown to save thousands of lives a year
por: Iskandar Idris
Publicado: (2024)

Potential new therapies to preserve lean muscle mass loss when used in combination with glucagon‐like peptide 1 (GLP‐1) receptor agonist being studied
por: Iskandar Idris
Publicado: (2024)

The US Food and Drug administration has approved resmetirom as the first drug to treat metabolic dysfunction‐associated steatohepatitis (MASH)
por: Iskandar Idris
Publicado: (2024)

Adults who are overweight or obese may experience greater pain intensity compared with normal weight individuals?
por: Iskandar Idris
Publicado: (2024)

Tirzepatide shown to be effective at reducing sleep disturbances in patients with obstructive sleep apnoea
por: Iskandar Idris
Publicado: (2024)

Hybrid closed‐loop therapy significantly improved maternal glucose control during pregnancy complicated by type 1 diabetes
por: Iskandar Idris
Publicado: (2024)

The glucagon like peptide‐1 linked to nonarteritic anterior ischemic optic neuropathy
por: Iskandar Idris
Publicado: (2024)

Potential role of glucagon like peptide (GLP)‐1 receptor agonist to reduce risk of colorectal cancer?
por: Iskandar Idris
Publicado: (2024)

Can diet and exercise intervention prevent type 2 diabetes in individuals with a high genetic risk?
por: Iskandar Idris
Publicado: (2024)

Appropriate timing of exercise for adults with obesity including those with type 2 diabetes
por: Iskandar Idris
Publicado: (2024)

Extension study from DIRECT showed ongoing remission rate from type 2 diabetes in some patient following very low calorie diet at 5 years
por: Iskandar Idris
Publicado: (2024)

Tirzepatide shown to improve clinical outcomes for patients with heart failure with preserved ejection fraction (HFpEF) and obesity
por: Iskandar Idris
Publicado: (2024)

Glucagon like peptide‐1 (GLP‐1) therapy is associated with reduced risk of developing cirrhosis and liver cancer in people with type 2 diabetes with chronic liver disease
por: Iskandar Idris
Publicado: (2024)

Epigenetic changes shown to cause type 2 diabetes
por: Iskandar Idris
Publicado: (2024)

Real world study provided reassurance of the safety of GLP‐1 therapy on mental health and suicide risk
por: Iskandar Idris
Publicado: (2024)

Precision medicine approach to detect obese people who are at high risk of developing diabetes
por: Iskandar Idris
Publicado: (2024)

Real world data showed that the dual GLP gip agonist, Tirzepatide is associated with lower mortality, cardiovascular events and adverse kidney events compared with GLP‐1 analogue
por: Iskandar Idris
Publicado: (2024)

Fenofibrate shown to reduce progression of diabetic retinopathy
por: Iskandar Idris
Publicado: (2024)

Issue Information
Publicado: (2024)

Issue Information
Publicado: (2024)

Issue Information
Publicado: (2024)

Issue Information
Publicado: (2024)

Issue Information
Publicado: (2024)

Issue Information
Publicado: (2024)

Issue Information
Publicado: (2024)

Issue Information
Publicado: (2024)

The latest evidence and guidance in lifestyle and surgical interventions to achieve weight loss in people with overweight or obesity
por: Iskandar Idris, et al.
Publicado: (2025)

Dietary BCAA supplementation counteracts the beneficial effects of long‐term aerobic exercise against obesity and associated metabolic disorders by suppressing FGF21 expression
por: Jun Zhang, et al.
Publicado: (2025)

Risk of new‐onset diabetes and efficacy of pharmacological weight loss therapy
por: Filipe A. Moura, et al.
Publicado: (2024)

Evaluation of leptin treatment on maintenance of body weight loss in diet‐induced obese mice
por: Danna M. Breen, et al.
Publicado: (2025)

Hepatic GCGR is required for the superior weight loss and metabolic effects of a structurally related analogue of the dual GCGR / GLP ‐ 1R agonist survodutide in mice
por: Fen Long, et al.
Publicado: (2025)

Cardiometabolic risk effects of weight‐loss medications: An updated network meta‐analysis
por: Juan Wang, et al.
Publicado: (2025)

A novel, centrally acting mammalian aminosterol, ENT ‐03, induces weight loss in obese and lean rodents
por: Denise Barbut, et al.
Publicado: (2024)

Quantitative proteomics identifies plasma protein alterations that associate with metabolic and thrombotic profile changes after bariatric surgery
por: Hasnain Ahmed, et al.
Publicado: (2025)

Actual weight loss trajectories after bariatric surgery compared with the SOPHIA prediction tool: An observational comparison study
por: Adhithya Sankar, et al.
Publicado: (2025)

The Goldilocks for chronic weight management—Balancing quantity with quality of weight loss
por: Kim Henriksen, et al.
Publicado: (2025)

Glycaemic and weight effects of metabolic surgery or semaglutide in diabetes dosage for patients with type 2 diabetes
por: Erik Stenberg, et al.
Publicado: (2024)

Incretin mimetics for weight loss forgive nonadherence
por: Anıl Cengiz, et al.
Publicado: (2025)

Survey among adult users of semaglutide for weight loss in Denmark: User characteristics, treatment expectations and experienced effects
por: Malene Svoldgaard Sørensen, et al.
Publicado: (2025)

Real‐world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP ‐ 1RA ‐based weight‐loss therapies
por: Reimar W. Thomsen, et al.
Publicado: (2025)